
Alvotech S.A (ALVO) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
173.2M
Gross Profit
99.4M
57.39%
Operating Income
18.1M
10.42%
Net Income
32.0M
18.49%
Balance Sheet Metrics
Total Assets
1.2B
Total Liabilities
1.5B
Shareholders Equity
-302.3M
Cash Flow Metrics
Operating Cash Flow
5.0M
Free Cash Flow
-10.8M
Revenue & Profitability Trend
Alvotech S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 489.7M | 91.4M | 83.0M | 36.8M | 66.6M |
Cost of Goods Sold | 185.3M | 160.9M | 64.1M | 0 | 0 |
Gross Profit | 304.4M | -69.4M | 18.9M | 36.8M | 66.6M |
Gross Margin % | 62.2% | -75.9% | 22.8% | 100.0% | 100.0% |
Operating Expenses | |||||
Research & Development | 171.3M | 210.8M | 180.6M | 191.0M | 148.1M |
Selling, General & Administrative | 61.5M | 76.6M | 186.7M | 84.1M | 58.9M |
Other Operating Expenses | -2.3M | -1.9M | -2.0M | -2.9M | -2.8M |
Total Operating Expenses | 230.5M | 285.4M | 365.4M | 272.2M | 204.2M |
Operating Income | 69.6M | -354.9M | -346.4M | -235.5M | -137.5M |
Operating Margin % | 14.2% | -388.1% | -417.3% | -640.3% | -206.5% |
Non-Operating Items | |||||
Interest Income | 4.6M | 4.8M | 912.0K | 19.0K | 215.0K |
Interest Expense | 154.0M | 133.2M | 77.5M | 113.0M | 97.5M |
Other Non-Operating Income | -134.2M | -166.2M | -114.7M | 200.8M | -53.7M |
Pre-tax Income | -217.6M | -651.0M | -551.6M | -149.2M | -291.8M |
Income Tax | 14.3M | -99.3M | -38.1M | -47.7M | -121.7M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -231.9M | -551.7M | -513.6M | -101.5M | -170.0M |
Net Margin % | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% |
Key Metrics | |||||
EBITDA | 101.9M | -334.6M | -341.7M | -221.2M | -125.7M |
EPS (Basic) | $-0.87 | $-2.43 | $-2.60 | $-0.92 | $-1.54 |
EPS (Diluted) | $-0.87 | $-2.43 | $-2.60 | $-0.92 | $-1.54 |
Basic Shares Outstanding | 266510345 | 227256469 | 197530769 | 110673309 | 110673309 |
Diluted Shares Outstanding | 266510345 | 227256469 | 197530769 | 110673309 | 110673309 |
Income Statement Trend
Alvotech S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 51.4M | 11.2M | 66.4M | 17.6M | 31.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 160.2M | 41.3M | 33.0M | 29.4M | 583.0K |
Inventory | 127.9M | 74.4M | 71.5M | 39.1M | 9.6M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 455.0M | 194.8M | 230.7M | 119.8M | 86.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 124.9M | 119.4M | 47.2M | 126.6M | 111.5M |
Goodwill | 43.3M | 43.2M | 48.9M | 46.2M | 33.2M |
Intangible Assets | 20.6M | 19.1M | 25.7M | 21.5M | 6.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 324.7M | 349.0M | 243.7M | 183.6M | 134.9M |
Total Non-Current Assets | 766.4M | 755.2M | 597.7M | 478.2M | 388.3M |
Total Assets | 1.2B | 950.1M | 828.4M | 598.0M | 474.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 67.1M | 80.6M | 49.2M | 28.6M | 12.0M |
Short-term Debt | 42.2M | 47.7M | 25.1M | 10.1M | 8.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 193.4M | 261.0M | 167.3M | 111.8M | 51.0M |
Non-Current Liabilities | |||||
Long-term Debt | 1.1B | 1.0B | 780.0M | 513.0M | 668.9M |
Deferred Tax Liabilities | 1.8M | 53.0K | 309.0K | 150.0K | 217.0K |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 1.4B | 1.6B | 1.2B | 621.8M | 1.3B |
Total Liabilities | 1.6B | 1.9B | 1.4B | 733.6M | 1.3B |
Equity | |||||
Common Stock | 2.8M | 2.3M | 2.1M | 135.0K | 73.0K |
Retained Earnings | -2.4B | -2.2B | -1.7B | -1.1B | -1.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -412.8M | -932.5M | -564.4M | -135.6M | -867.2M |
Key Metrics | |||||
Total Debt | 1.2B | 1.1B | 805.1M | 523.1M | 676.8M |
Working Capital | 261.6M | -66.1M | 63.4M | 8.0M | 35.2M |
Balance Sheet Composition
Alvotech S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -231.9M | -551.7M | -513.6M | -101.5M | -170.0M |
Depreciation & Amortization | 31.3M | 24.2M | 20.4M | 18.2M | 16.4M |
Stock-Based Compensation | 7.6M | 18.0M | 10.3M | 0 | 0 |
Working Capital Changes | -274.9M | -5.4M | -64.3M | -6.8M | 32.5M |
Operating Cash Flow | -161.2M | -484.2M | -378.5M | -157.1M | -68.8M |
Investing Activities | |||||
Capital Expenditures | -53.7M | -33.1M | -37.5M | -20.5M | -7.4M |
Acquisitions | 12.0M | - | - | 0 | -5.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -15.5M | -33.1M | -52.4M | -20.5M | -17.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 920.8M | 278.8M | 193.7M | 113.8M | 30.0M |
Debt Repayment | -768.8M | -107.6M | -95.9M | -44.8M | -9.0M |
Financing Cash Flow | 282.9M | 294.9M | 374.9M | 254.8M | 55.4M |
Free Cash Flow | -293.8M | -358.7M | -361.4M | -268.8M | -86.3M |
Net Change in Cash | 106.2M | -222.3M | -56.0M | 77.3M | -30.8M |
Cash Flow Trend
Alvotech S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
38.04
Forward P/E
43.75
Price to Sales
4.85
PEG Ratio
43.75
Profitability Ratios
Profit Margin
11.26%
Operating Margin
10.42%
Return on Equity
56.17%
Return on Assets
2.83%
Financial Health
Current Ratio
1.82
Debt to Equity
-7.32
Beta
0.11
Per Share Data
EPS (TTM)
$0.23
Book Value per Share
$-0.56
Revenue per Share
$1.98
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alvo | 2.7B | 38.04 | - | 56.17% | 11.26% | -7.32 |
Zoetis | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 43.4B | 21.51 | 5.46 | 9.38% | 13.81% | 53.41 |
Elanco Animal Health | 8.7B | 19.91 | 1.28 | 6.83% | 9.68% | 62.13 |
Regencell Bioscience | 6.1B | - | 878.57 | -47.77% | 0.00% | 0.01 |
Alkermes plc | 4.8B | 14.03 | 2.95 | 23.94% | 23.15% | 4.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.